CXCL8 and central nervous system cancer: To investigate whether CXCL8 differed in GBM and LGG, we examined the CXCL8 expression levels in patients with gliomas of different WHO stages and found that CXCL8 expression was not significantly different between WHO II and WHO III (P = 0.15) but was significantly higher between WHO II and WHO IV (P < 2.22e−16) and between WHO III and WHO IV (P < 2.22e−16) were significantly different (Fig. 2D), suggesting that there was a significant expression difference of CXCL8 between low-grade gliomas and high-grade gliomas.